A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B).
AGMB101-01-CL-102
Phase 1 other active
Quick answer
A study to evaluate the safety and tolerability of single ascending doses of AGMB-101 in healthy participants (Part A) and patients with liver cirrhosis (Part B). for liver cirrhosis is a Phase 1 program (other) at Agomab Therapeutics NV with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Agomab Therapeutics NV
- Indication
- liver cirrhosis
- Phase
- Phase 1
- Modality
- other
- Status
- active